Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal Journal of Pharmaceutical and Sciences.
Shadrina , Jahra Almas
Unknown Affiliation
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Nursing Public Health

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Review Artikel: Perbandingan Efektivitas dan Efek Samping Pembrolizumab Kombinasi Kemoterapi Dengan Kemoterapi Tunggal Dalam Pengobatan Non-Small Cell Lung Cancer (NSCLC) Dzannuba, Fadya Laila; Hilmi , Indah Laily; Sudarjat , Hadi; Shadrina , Jahra Almas; Affandhy , Adhwa’a Kaylla
Journal of Pharmaceutical and Sciences JPS Volume 8 Nomor 2 (2025)
Publisher : Fakultas Farmasi Universitas Tjut Nyak Dhien

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36490/journal-jps.com.v8i2.684

Abstract

This review article aims to compare the effectiveness and side effects of pembrolizumab combined with chemotherapy versus chemotherapy alone in the treatment of advanced Non-Small Cell Lung Cancer (NSCLC). A systematic review was conducted using literature published between 2015 and 2024. Relevant studies were identified through databases such as Google Scholar, using keywords like "Pembrolizumab," "Side Effects," "Effectiveness," "Overall Survival (OS)," and "Progression-Free Survival (PFS)." The results showed that pembrolizumab combined with chemotherapy significantly improved Overall Survival (OS) and Progression-Free Survival (PFS) compared to chemotherapy alone. However, this combination therapy was associated with a higher frequency of side effects, such as pneumonitis and hypothyroidism. In conclusion, pembrolizumab combined with chemotherapy offers superior efficacy in prolonging survival and controlling disease progression in advanced NSCLC. However, its use requires careful patient selection and close monitoring of toxicity. These findings support pembrolizumab as a promising first-line therapy for advanced NSCLC.
Co-Authors Affandhy , Adhwa’a Kaylla Dzannuba, Fadya Laila Hilmi , Indah Laily Sudarjat , Hadi